CHENNAI, March 4 (Reuters) - An Indian patent appeals board
dismissed on Monday Bayer AG's petition against a
government decision to allow a domestic company to sell cheap
copycat versions of cancer drug Nexavar, delivering a blow to
global drugmakers' monopolies on high-priced medicines.
Last year, the Indian patents office, under a mechanism
called "compulsory licence", allowed Natco Pharma to
sell generic Nexavar at 8,800 rupees ($160) for a month's dose
-- a fraction of Bayer's price of 280,000 rupees.
Bayer challenged this decision with the Intellectual
Property Appellate Board (IPAB) in the southern city of Chennai.
Although dismissing the petition, the board did order Natco
Pharma to pay a royalty of 7 percent on sales of generic Nexavar
to Bayer, an increase from the 6 percent royalty that had
earlier been set.